Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117351 · ClinicalTrials.gov registry record · Phase 2
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
A Phase 2 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00117351 is a Phase 2 study that was terminated before completion, run by Millennium Pharmaceuticals.
The verdict
NCT00117351, a Phase 2 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
This study will evaluate the safety and efficacy of VELCADE in patients with previously treated stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features.
Interventions
- DRUG VELCADE
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-04 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117351
The ClinicalTrials.gov registry entry for NCT00117351 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VELCADE is the first listed.
NCT00117351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00117351 about?
NCT00117351 is a clinical study titled "VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features". This study will evaluate the safety and efficacy of VELCADE in patients with previously treated stage IIIB and IV bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features.
What is the current status of trial NCT00117351?
This trial is currently terminated. It is a Phase 2 study. The study started on 2005-04. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00117351?
The interventions under investigation include: VELCADE (DRUG).
Who is sponsoring clinical trial NCT00117351?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.